Next Generation Sequencing Market To Reach $42.25 Billion By 2033

October 2025 | Report Format: Electronic (PDF)

Next Generation Sequencing Market Growth & Trends

The global next-generation sequencing market size is estimated to reach USD 42.25 billion by 2033, expanding at a CAGR of 18.0% from 2025 to 2033, according to a new report by Grand View Research, Inc. Next-generation Sequencing (NGS) is a parallel processing technique that can establish the sequence of nucleotides in a whole genome with scalability, ultra-high capacity, and fast speed. Furthermore, in the healthcare industry, NGS is gradually being incorporated into medical laboratory research, screening, and disease diagnoses. In personalized medicine, it has been frequently utilized to accelerate the drug research process.

Different potential sequencing methods such as RNA sequencing, whole-genome sequencing, and whole-exome and targeted sequencing amongst others are prominently used by researchers to get comprehensive sample analysis. When compared to the traditional Sanger sequencing technology, NGS is less expensive and provides higher throughput for DNA sequencing. The growing automation in the pre-sequencing protocols, post-sequencing protocols, and data analysis is also projected to have a positive impact on the NGS market. The utilization of novel platforms for the development of personalized medicine by medical analysis at a genetic level is also a significant factor, which is expected to enhance demand for NGS over the forecast period.

Besides, there are other significant growth trends that are being witnessed in the sequencing industry, such as the development of personalized medicine and companion diagnostics, growing advancements in cloud computing, and data integration. Furthermore, the easy availability of genomic and proteomic data has poised this market to exhibit potentially high-value avenues and opportunities for growth over the forecast period. The market growth is also being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Such a substantial rise in the number of cancer cases is estimated to leverage cancer research which will eventually accelerate the NGS market growth.

The NGS diagnostic techniques have the potential to determine a virus's genomic sequence and aid scientists in their understanding of mutations. Furthermore, throughout the COVID-19 epidemic, governments across the globe have been collaborating with the corporate sector to introduce NGS technology to the market as a viable diagnostic tool. The US Food and Drug Administration granted Illumina Inc. a case of emergency use permit for the first COVID-19 diagnostic using the next-generation sequence technique in June 2020. The Illumina COVIDSeq Test for qualitative identification of SARS-CoV-2 RNA has been approved by the FDA. As a result, the usage of next-generation sequencing (NGS) technologies is projected to increase during the pandemic.

key Request a free sample copy or view the report summary: Next Generation Sequencing Market Report

Next Generation Sequencing Market Report Highlights

The consumables segment held the largest market share in 2024 and is expected to grow at the fastest CAGR from 2025 to 2033.
The oncology segment held the largest revenue share of 31.71% in 2024, driven by the critical role of genomics data analysis in cancer research, diagnostics, and targeted therapy development.
The sequencing segment held the highest market share of 64.10% in 2024 and is expected to grow with the fastest rate over the forecast period.
North America next generation sequencing market dominated the respective global market with the largest share of 44.74% in 2024 due to the rising R&D activities across the developed countries coupled with the presence of numerous end-use application manufacturers in the pharmaceuticals, food & beverage, and personal care & cosmetics sector
The academic research segment held the largest revenue share of 36.15% in 2024.

Next Generation Sequencing Market Segmentation

Grand View Research has segmented the next-generation sequencing market based on technology, product, workflow, end-use, and region:

Next Generation Sequencing Technology Outlook (Revenue, USD Million, 2021 - 2033)

WGS
Whole Exome Sequencing
Targeted Sequencing & Resequencing
- DNA-based
- RNA-based
Others

Next Generation Sequencing Product Outlook (Revenue, USD Million, 2021 - 2033)

Platform
- Sequencing
- Data Analysis
Consumables
- Sample Preparation
- Target Enrichment
- Others

Next Generation Sequencing Application Outlook (Revenue, USD Million, 2021 - 2033)

Oncology
- Diagnostics and Screening
  - Oncology Screening
    - Sporadic Cancer
    - Inherited Cancer
  - Companion Diagnostics
  - Other Diagnostics
- Research Studies
Clinical Investigation
- Infectious Diseases
- Inherited Diseases
- Idiopathic Diseases
- Non-Communicable/Other Diseases
Reproductive Health
- NIPT
  - Aneuploidy
  - Microdeletions
- PGT
- Newborn Genetic Screening
- Single Gene Analysis
HLA Typing/Immune System Monitoring
Metagenomics, Epidemiology & Drug Development
Agrigenomics & Forensics
Consumer Genomics

Next Generation Sequencing Workflow Outlook (Revenue, USD Million, 2021 - 2033)

Pre-Sequencing
- Nucleic Acid Extraction
- Library Preparation
Sequencing
NGS Data Analysis
- NGS Primary Data Analysis
- NGS Secondary Data Analysis
- NGS Tertiary Data Analysis